Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-Hodgkin Lymphoma
100%
Combination Chemotherapy
100%
Intermediate Grade
100%
Oral Combination
100%
AIDS-related
100%
Chemotherapy Regimen
80%
Flow Cytometry
40%
Cell-Associated
40%
P24 Antigen
40%
Quality of Life Assessment
40%
Brief Symptom Inventory
40%
Patient Demographics
20%
Confidence Interval
20%
Complete Remission
20%
Survival Rate
20%
Clinical Assessment
20%
Median Survival
20%
Response Rate
20%
Objective Response Rate
20%
Performance Status
20%
Indirect Immunofluorescence
20%
Complete Response
20%
Predictor Variables
20%
Prognostic Value
20%
Mortality Rate
20%
Biopsy-proven
20%
Orally Administered
20%
Myelosuppression
20%
Etoposide
20%
Cytotoxic Chemotherapy
20%
Partial Remission
20%
Cyclophosphamide
20%
Lymphoma
20%
Procarbazine
20%
Survival Duration
20%
Separation Analysis
20%
CD4 Lymphocyte Count
20%
Eastern Cooperative Oncology Group
20%
Treatment-related Mortality
20%
Randomized Controlled Clinical Trial
20%
Index Cancer
20%
Oral Regimen
20%
Quality of Life Issues
20%
Severe Toxicity
20%
Living Index
20%
High-grade non-Hodgkin Lymphoma
20%
Thrush
20%
Oral Chemotherapy
20%
Lomustine
20%
Toxicity Response
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Nonhodgkin Lymphoma
100%
Chemotherapy Regimens
100%
Flow Cytometry
50%
Symptom
50%
Remission
50%
Malignant Neoplasm
25%
Mortality Rate
25%
Survival Rate
25%
Bone Marrow Suppression
25%
Cyclophosphamide
25%
Controlled Clinical Trial
25%
Etoposide
25%
Procarbazine
25%
Cytotoxic Chemotherapy
25%
Lomustine
25%
Thrush
25%
Nursing and Health Professions
Nonhodgkin Lymphoma
100%
Combination Chemotherapy
100%
Flow Cytometry
40%
Remission
40%
Quality of Life Assessment
40%
Brief Symptom Inventory
40%
Antigen P24
40%
Malignant Neoplasm
20%
Patient Population
20%
Confidence Interval
20%
Clinical Assessment
20%
Survival Rate
20%
Quality of Life
20%
Predictor Variable
20%
Mortality Rate
20%
Biopsy
20%
Thrush
20%
Cyclophosphamide
20%
Bone Marrow Suppression
20%
CD4 Lymphocyte Count
20%
Etoposide
20%
Procarbazine
20%
Lomustine
20%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Combination Chemotherapy
100%
Chemotherapy Regimens
80%
Flow Cytometry
40%
Malignant Neoplasm
20%
Health Care Cost
20%
Patient Population
20%
Biopsy
20%
Quality of Life
20%
Clinical Assessment
20%
Mortality Rate
20%
Survival Rate
20%
Lymphocyte
20%
Oncology
20%
Cytotoxic Chemotherapy
20%
Controlled Clinical Trial
20%
Cyclophosphamide
20%
Etoposide
20%
Procarbazine
20%
Immunofluorescence
20%
Oral Candidiasis
20%
Bone Marrow Suppression
20%
Immunology and Microbiology
Antigen P24
100%
Immunofluorescence
50%
Survival Rate
50%
Mortality Rate
50%
Cyclophosphamide
50%
CD4 Lymphocyte Count
50%